Last updated on May 2018

Ketamine for Reduction of Alcoholic Relapse


Brief description of study

96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation. Patients will be assessed at 3 and 6 months on a range of psychological and biological variables. Primary endpoints will be % days abstinent at 3 and 6 months and relapse rates at 6 months. Secondary endpoints include depressive symptoms, craving, quality of life.

Clinical Study Identifier: NCT02649231

Contact Investigators or Research Sites near you

Start Over

Amy McAndrew, PhD

NIHR Exeter Clinical Research Facility
Exeter, United Kingdom
  Connect »

Beth Marsh, PhD

NIHR/Wellcome UCLH Research Facility
London, United Kingdom
  Connect »